Clinical trial
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity…
NCT00380692 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00380692 |
|---|---|
| Title | Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder |
| Official title | A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Autistic Disorder, Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | Atomoxetine, Placebo |
| Enrollment | 97 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 26, 2006 |
| Last update posted | May 11, 2010 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: